Skip to main content
. 2021 Dec 16;2(4):618–653. doi: 10.1002/mco2.104

TABLE 2.

Summary of part of recent NF‐κB pathway‐related inhibitor clinical trials

Cancer type Target Main drug Phase NCT number Enrollment Ref
MM 20S PI Ixazomib III NCT01564537 722 425
KRAS G12D‐mutant/p53‐deficient NSCLC 26S PI Bortezomib II NCT01833143 16 448
Classic Hodgkin lymphoma 26S PI Bortezomib II NCT00967369 20 /
Head and neck cancer 26S PI Bortezomib I NCT00011778 25 /
MM SINE+26S PI Selinexor + bortezomib + dexamethasone II NCT02343042 42 449
Head and neck adenoid cystic carcinoma 26S PI Bortezomib II NCT00077428 25 450
Advanced oesophagogastric adenocarcinoma 26S PI Bortezomib I / 18 451
Advanced gastric adenocarcinoma 26S PI Bortezomib II / 16 452
Endocrine‐resistant metastatic breast cancer 26S PI Bortezomib II / 9 453
Locally recurrent or metastatic squamous cell carcinoma of the head and neck 26S PI Bortezomib II / 61 454
Malignant gliomas 26S PI + DNA alkylating agents Bortezomib + Temozolomide II / 10 455
Plasma cell myeloma 20S PI Ixazomib II NCT02765854 90 /
Waldenström's macroglobulinemia 20S PI Ixazomib II NCT02400437 26 456
Waldenström's macroglobulinemia 20S PI+BTK Carfilzomib + ibrutinib III NCT04263480 184 /
Advanced solid tumors Na‐K ATPase PBI‐05204 I / 46 457
CLL BTK Ibrutinib II NCT01500733 86 458
Early‐stage chronic lymphocytic leukemia NF‐κB inhibitor Omega‐3 fatty acids II NCT00899353 16 459
Advanced solid tumors and lymphomas IKK inhibitor Bardoxolone methyl I / 44 460
Primary CNS lymphoma BTK Ibrutinib I NCT02315326 13 461
Waldenström's macroglobulinemia BTK BGB‐3111 III NCT03053440 229 /
NSCLC RANKL Denosumab III NCT02129699 509 462
Giant cell tumor of bone RANKL Denosumab III NCT03259152 30 /
Urothelial carcinoma RANKL Denosumab II NCT03520231 50 /
Melanoma RANKL Denosumab I NCT03161756 72 /
MM BCL‐2 Venetoclax I/II NCT01794520 51 463
MM IL‐1R Anakinra I NCT02492750 14 /
ALL Phosphodiesterase Pentoxifylline III NCT02451774 44 /
Triple negative breast cancer CD40 CDX‐1140 I NCT05029999 45 /
Metastatic melanoma CD40 APX005M I NCT03597282 22 /
NSCLC CD40 APX005M I NCT03123783 400 /
Soft tissue sarcoma CD40 APX005M II NCT03719430 27
Metastatic pancreatic adenocarcinoma CD40 APX005M I NCT03214250 129 464
Melanoma CD40 SEA‐CD40 II NCT04993677 200 /
NSCLC CD40 SEA‐CD40 I NCT02376699 159 /
Melanoma CD40 CP‐870,893 I NCT01103635 25 /
DLBCL CD40 SGN‐40 II NCT00529503 151 /
Non‐Hodgkin lymphoma, DLBCL BAFF‐R VAY736 I NCT04903197 86 /

Abbreviations: ALL, acute lymphoblastic leukemia; BTK, Bruton's tyrosine kinase; CLL, chronic lymphocytic leukemia; diffuse large B‐cell lymphoma. All NCT numbers were obtained from https://clinicaltrials.gov/; IKK, IkappaB kinases; MM, multiple myeloma; NSCLC, non‐small cell lung cancer; PI, proteasome inhibitor; RANKL, receptor activator of NF‐κB ligand; SINE, selective inhibitor of nuclear export.